Literature DB >> 9554686

End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy.

D R Powers1, J D Wallin.   

Abstract

During the past few years, it has become apparent that there are factors that place a person at greater risk for the development and progression of renal failure. This has been documented since the early 1980s by the United States Renal Data System that has collected data confirming that end-stage renal disease occurs at a greater rate in certain subpopulations of Americans. It is evident from an examination of the data that African Americans and American Indians have an incidence of end-stage renal disease that is not proportional to their percentage of the total population. In fact, African Americans and American Indians are reported to have at least a 4-fold greater incidence of end-stage renal disease than white Americans. There have been 5 factors identified: hypertension, glucose intolerance, insulin resistance, salt sensitivity, and hyperlipidemia, which may play a greater role in these subpopulations. In addition, as with other populations, lifestyle issues may serve to alter these primary risk factors or may act as direct modulators of renal disease progression. There is also a possibility that interactions between risk factors frequently occur that may modify the development or progression of the disease. This article reviews these risk factors and emphasizes the interaction between hypertension and the other factors. In addition, the effects of antihypertensive agents on risk factors and on renal outcome are emphasized. Where possible, issues specific to African Americans and American Indians are underscored; however, one must accept that the database on these populations is only now developing. This review should help the clinician make appropriate choices when prescribing antihypertensive therapy for patients who may be at risk of developing progressive renal failure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554686     DOI: 10.1001/archinte.158.7.793

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

1.  Racial/ethnic variations in women's health: the social embeddedness of health.

Authors:  David R Williams
Journal:  Am J Public Health       Date:  2002-04       Impact factor: 9.308

2.  Racial/ethnic variations in women's health: the social embeddedness of health.

Authors:  David R Williams
Journal:  Am J Public Health       Date:  2008-09       Impact factor: 9.308

3.  African American kidney transplantation survival: the ability of immunosuppression to balance the inherent pre- and post-transplant risk factors.

Authors:  Gregory E Malat; Christine Culkin; Aniruddha Palya; Karthik Ranganna; Mysore S Anil Kumar
Journal:  Drugs       Date:  2009-10-22       Impact factor: 9.546

4.  Hypertensive cardiovascular disease in African Americans.

Authors:  R K Wali; M R Weir
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

Review 5.  Diabetic nephropathy in African-American patients.

Authors:  Errol D Crook; Sejal R Patel
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

Review 6.  Genetics of diabetes complications.

Authors:  Donald W Bowden
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

7.  Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes.

Authors:  Allison B Rosen; Andrew J Karter; Jennifer Y Liu; Joe V Selby; Eric C Schneider
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

Review 8.  Kidney disease in the Hispanic population: facing the growing challenge.

Authors:  Julio E Benabe; Elena V Rios
Journal:  J Natl Med Assoc       Date:  2004-06       Impact factor: 1.798

9.  Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension.

Authors:  Ali Jawa; Senthil Nachimuthu; Merri Pendergrass; Sunil Asnani; Vivian Fonseca
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.